Literature DB >> 23229466

Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation?

R Sapir-Koren1, G Livshits.   

Abstract

Declining estrogen levels during menopause are widely considered to be a major cause of age-dependent bone loss, which is primarily manifested by increased bone resorption by osteoclasts. We present accumulating evidence supporting another aspect of metabolic bone loss, suggesting that the combined interaction between age-dependent factors, namely, estrogen deficiency and reduced day-by-day activity/mechanical stimulation, directly leads to a reduction in anabolic processes. Such decreased bone formation results in diminished bone strength and failure to maintain the load-bearing competence of a healthy skeleton and to postmenopausal osteoporosis disorder. Estrogen receptors (ERs), as mediators of estrogenic actions, are essential components of bone osteocyte and osteoblast mechano-adaptive responses. ER expression appears to be upregulated by adequate circulating estrogen levels. ERα signaling pathways participate in the mechanotransduction response through obligatory "non-genomic" actions that occur independently of estrogen binding to ER and by a potentially "genomic", estrogen-dependent mode. The experimental data indicate that cross talk between the ERα-"non-genomic" and Wnt/β-catenin signaling pathways constitutes the major regulatory mechanism. This interaction uses mechanically and ER-induced prostaglandin E2 as a mediator for the downregulation of osteocyte production of sclerostin. Sclerostin suppression, in turn, is a central prerequisite for load-induced formation and mineralization of the bone matrix. It is therefore plausible that future strategies for preventing and treating postmenopausal osteoporosis may use estrogenic compounds (such as selective estrogen receptor modulators or phytoestrogens) with physical activity, to complement antiresorptive therapy, aimed at stopping further bone loss and possibly even reversing it by stimulation of bone gain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229466     DOI: 10.1007/s00198-012-2208-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  124 in total

1.  The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.

Authors:  Kimihiko Sawakami; Alexander G Robling; Minrong Ai; Nathaniel D Pitner; Dawei Liu; Stuart J Warden; Jiliang Li; Peter Maye; David W Rowe; Randall L Duncan; Matthew L Warman; Charles H Turner
Journal:  J Biol Chem       Date:  2006-06-20       Impact factor: 5.157

Review 2.  Ten years muscle-bone hypothesis: what have we learned so far?--almost a festschrift--.

Authors:  J Rittweger
Journal:  J Musculoskelet Neuronal Interact       Date:  2008 Apr-Jun       Impact factor: 2.041

3.  Mechanical effects on the skeleton: are there clinical implications?

Authors:  M R Forwood
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

4.  Tibial compression is anabolic in the adult mouse skeleton despite reduced responsiveness with aging.

Authors:  Maureen E Lynch; Russell P Main; Qian Xu; Thomas L Schmicker; Mitchell B Schaffler; Timothy M Wright; Marjolein C H van der Meulen
Journal:  Bone       Date:  2011-05-27       Impact factor: 4.398

5.  Fluid flow induction of cyclo-oxygenase 2 gene expression in osteoblasts is dependent on an extracellular signal-regulated kinase signaling pathway.

Authors:  Sunil Wadhwa; Stephen L Godwin; Donald R Peterson; Mary A Epstein; Lawrence G Raisz; Carol C Pilbeam
Journal:  J Bone Miner Res       Date:  2002-02       Impact factor: 6.741

6.  Effect of ovarian steroid deficiency on oestrogen receptor alpha expression in bone.

Authors:  J A Hoyland; C Baris; L Wood; P Baird; P L Selby; A J Freemont; I P Braidman
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

7.  Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen.

Authors:  Gul Zaman; Helen L Jessop; Mariusz Muzylak; Roberto L De Souza; Andrew A Pitsillides; Joanna S Price; Lance L Lanyon
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

8.  Estrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle.

Authors:  Kristen A Baltgalvis; Sarah M Greising; Gordon L Warren; Dawn A Lowe
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

9.  Modulation of Wnt signaling influences fracture repair.

Authors:  David E Komatsu; Michelle N Mary; Robert Jason Schroeder; Alex G Robling; Charles H Turner; Stuart J Warden
Journal:  J Orthop Res       Date:  2010-07       Impact factor: 3.494

Review 10.  Sclerostin: current knowledge and future perspectives.

Authors:  M J C Moester; S E Papapoulos; C W G M Löwik; R L van Bezooijen
Journal:  Calcif Tissue Int       Date:  2010-05-15       Impact factor: 4.333

View more
  9 in total

Review 1.  Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?

Authors:  R Sapir-Koren; G Livshits
Journal:  Osteoporos Int       Date:  2014-07-17       Impact factor: 4.507

Review 2.  Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.

Authors:  Yongyong Yan; Liping Wang; Linhu Ge; Janak L Pathak
Journal:  Curr Osteoporos Rep       Date:  2020-02       Impact factor: 5.096

3.  Effect of serum from postmenopausal women with osteoporosis exhibiting the Kidney-Yang deficiency pattern on bone formation in an hFOB 1.19 human osteoblastic cell line.

Authors:  Yachan Li; Wenna Liang; Xihai Li; Bizhen Gao; Huijuan Gan; Lianhua Yin; Jianying Shen; Jie Kang; Shanshan Ding; Xuejuan Lin; Linghong Liao; Candong Li
Journal:  Exp Ther Med       Date:  2015-07-03       Impact factor: 2.447

4.  Age-related effects on the potency of human adipose-derived stem cells: creation and evaluation of superlots and implications for musculoskeletal tissue engineering applications.

Authors:  Josephine C Bodle; Stephanie D Teeter; Brandon H Hluck; Joseph W Hardin; Susan H Bernacki; Elizabeth G Loboa
Journal:  Tissue Eng Part C Methods       Date:  2014-05-01       Impact factor: 3.056

5.  Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors.

Authors:  Wonjin Kim; Yoonjung Chung; Se Hwa Kim; Sehee Park; Jae Hyun Bae; Gyuri Kim; Su Jin Lee; Jo Eun Kim; Byeong Woo Park; Sung Kil Lim; Yumie Rhee
Journal:  Endocrinol Metab (Seoul)       Date:  2014-07-02

6.  Estrogen inhibits starvation-induced apoptosis in osteocytes by a redox-independent process involving association of JNK and glutathione S-transferase P1-1.

Authors:  Vladana Domazetovic; Filippo Fontani; Gemma Marcucci; Teresa Iantomasi; Maria Luisa Brandi; Maria Teresa Vincenzini
Journal:  FEBS Open Bio       Date:  2017-04-05       Impact factor: 2.693

Review 7.  Potential Role of Perilacunar Remodeling in the Progression of Osteoporosis and Implications on Age-Related Decline in Fracture Resistance of Bone.

Authors:  Katharina Jähn-Rickert; Elizabeth A Zimmermann
Journal:  Curr Osteoporos Rep       Date:  2021-06-12       Impact factor: 5.096

8.  Quantification of Alterations in Cortical Bone Geometry Using Site Specificity Software in Mouse models of Aging and the Responses to Ovariectomy and Altered Loading.

Authors:  Gabriel L Galea; Sion Hannuna; Lee B Meakin; Peter J Delisser; Lance E Lanyon; Joanna S Price
Journal:  Front Endocrinol (Lausanne)       Date:  2015-04-23       Impact factor: 5.555

9.  Osteocyte Wnt/β-catenin pathway activation upon mechanical loading is altered in ovariectomized mice.

Authors:  Erica Jackson; Nuria Lara-Castillo; Mohammed P Akhter; Mark Dallas; JoAnna M Scott; Thiagarajan Ganesh; Mark L Johnson
Journal:  Bone Rep       Date:  2021-09-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.